Public Employees Retirement System of Ohio Makes New Investment in Arcturus Therapeutics Holdings Inc. $ARCT

Public Employees Retirement System of Ohio acquired a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 34,050 shares of the biotechnology company’s stock, valued at approximately $229,000. Public Employees Retirement System of Ohio owned about 0.12% of Arcturus Therapeutics as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in ARCT. BlackRock Inc. acquired a new stake in Arcturus Therapeutics in the second quarter valued at $17,566,000. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Arcturus Therapeutics by 12.9% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,288,935 shares of the biotechnology company’s stock worth $17,671,000 after purchasing an additional 262,347 shares during the last quarter. Heartland Advisors Inc. acquired a new stake in shares of Arcturus Therapeutics in the 2nd quarter valued at about $1,474,000. Hsbc Holdings PLC acquired a new stake in shares of Arcturus Therapeutics in the 2nd quarter valued at about $394,000. Finally, Amova Asset Management Americas Inc. lifted its position in shares of Arcturus Therapeutics by 12.9% during the first quarter. Amova Asset Management Americas Inc. now owns 2,288,935 shares of the biotechnology company’s stock worth $17,648,000 after purchasing an additional 262,347 shares during the last quarter. 94.54% of the stock is owned by institutional investors and hedge funds.

Arcturus Therapeutics Stock Performance

Arcturus Therapeutics stock opened at $14.73 on Friday. Arcturus Therapeutics Holdings Inc. has a 1 year low of $5.50 and a 1 year high of $24.17. The firm’s 50-day moving average is $9.57 and its 200-day moving average is $8.33. The company has a market cap of $418.63 million, a P/E ratio of -4.45 and a beta of 2.48.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Friday, August 7th. The biotechnology company reported ($0.84) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.16. Arcturus Therapeutics had a negative net margin of 317.62% and a negative return on equity of 46.54%. The business had revenue of $2.96 million during the quarter, compared to the consensus estimate of $3.11 million. As a group, sell-side analysts predict that Arcturus Therapeutics Holdings Inc. will post -3.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ARCT. Wall Street Zen upgraded Arcturus Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, August 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcturus Therapeutics in a report on Friday, July 17th. Finally, Roth Capital reiterated a “buy” rating and issued a $41.00 target price on shares of Arcturus Therapeutics in a research report on Wednesday, September 2nd. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.00.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.